Kaplan–Meier survival analysis of TCGA-READCOAD datasets revealed a markedly poorer progression-free interval in CRC patients with high PREX2 expression compared to those with low PREX2 expression (p = 0.0006, Fig. 1G). The gene discussed is PREX2; the disease is colorectal carcinoma.